Thyroid Cancer: Molecular Mechanisms and Targeted Therapies
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 112
Special Issue Editors
Interests: thyroid cancer; pituitary tumors; GH deficiency
Special Issues, Collections and Topics in MDPI journals
Interests: thyroid cancer; (neuro)endocrine tumors; polycystic ovary syndrome; pituitary tumors; GH deficiency
Special Issues, Collections and Topics in MDPI journals
Interests: thyroid surgery; endocrine tumors; endocrine surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Thyroid cancer (TC) is currently the most widespread endocrine disease and has had a rapidly increasing incidence in recent decades, becoming a relevant public health issue. Tumors derived from follicular cells constitute the majority of thyroid neoplasms, and the most common type, papillary thyroid cancer (PTC), represents 85–90% of all TC cases.
Recently, there has been a lot of evidence with a crucial impact on understanding the biology of thyroid cell function, changes in molecular mechanisms, and the regulation of genes/proteins that underlie thyroid cancer tumorigenesis. These research findings can help explain the clinical course of the disease, including the more aggressive trend in some cases, and are essential for managing this real public health problem. Treatment-related research has progressed, and new molecules have come into practice targeting specific genetic changes with a positive effect on survival rates.
The aim of the present collection is to identify novel molecular factors implicated in diagnostic or prognostic approaches to thyroid cancer, as well as new aspects of current treatment, in order to improve thyroid cancer management. Within this Special Issue, we encourage the submission of manuscripts related to the molecular understanding of thyroid cancer tumorigenesis and related to new perspectives in the targeted treatment.
This Special Issue includes, but is not limited to, the following:
- New molecular mechanisms and targets in thyroid cancer;
- Regulation of oncogenes and tumor suppressors involved in thyroid cancer;
- Role of noncoding RNA in thyroid cancer and biology (i.e., microRNA, lncRNA, and circRNA);
- New methods and models to study thyroid cell biology and tumorigenesis (i.e., gene editing and modulation);
- The importance and particular aspects of genetics and epigenetics in thyroid cancer;
- Upgrade in the classical surgical treatment of thyroid cancer;
- New aspects of first-line tyrosine kinase inhibitor treatment and salvage therapy in differentiated thyroid cancer (DTC);
- Novelties in combined therapy with inhibitors of different signaling pathways activated in DTC;
- Redifferentiation treatment in thyroid cancer refractory to radioactive iodine: new tracks and results;
- Immunotherapy in thyroid cancer: new findings;
- Physiopathological mechanisms and new therapies in other histological types of thyroid cancer;
- Artificial intelligence in nodular thyroid pathology.
Dr. Cristina Alina Silaghi
Prof. Dr. Carmen Emanuela Georgescu
Dr. Horaţiu Silaghi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- differentiated thyroid cancer
- medullary thyroid cancer
- anaplastic thyroid carcinoma
- advanced/metastatic thyroid cancer
- refractory thyroid cancer
- molecular biomarkers
- oncogenic signaling pathways
- thyroid cytology
- targeted therapy
- tyrosine kinase inhibitors
- immune checkpoint inhibitors
- therapeutic strategies
- thyroid cancer prognosis
- epigenomics in thyroid cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
